ArticleHuman vaccines & immunotherapeutics2023

Prospective, multi-center post-marketing surveillance cohort study to monitor the safety of the human papillomavirus-16/18 AS04-adjuvanted vaccine in Chinese girls and women aged 9 to 45 years, 2018-2020.

Qianhui Wu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.